Aslan Pharmaceuticals Ltd at Jefferies Healthcare Conference Transcript
So first of all, welcome to my presentation on ASLAN Pharmaceuticals. It's always a pleasure to be here at the Jefferies Conference.
So as ever, please pay attention to our disclaimers around the forward-looking statements, which you can also find on our website in our 20-F filings.
So just to summarize, ASLAN targets major inflammatory diseases, focusing on those that have significant unmet need. Our lead molecule, eblasakimab, targets the IL-13 receptor. It's a first-in-class antibody that has the potential to really improve upon current biologic use within allergic disease and in particular atopic dermatitis, so the lead indication here is atopic dermatitis. We have a Phase 2b program that's due to read out in early July. That's upcoming, and that's off the back of a proof-of-concept study that read out around 18 months ago.
Our second drug, farudodstat, is a DHODH inhibitor. This is a drug that we're developing in alopecia areata, and here, we kicked up a proof-of-concept study Phase 2 in this indication, which we're
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
